Biomarin Pharmaceutical Inc
NASDAQ:BMRN

Watchlist Manager
Biomarin Pharmaceutical Inc Logo
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Watchlist
Price: 64.26 USD 1.28% Market Closed
Market Cap: 12.2B USD
Have any thoughts about
Biomarin Pharmaceutical Inc?
Write Note

Relative Value

The Relative Value of one BMRN stock under the Base Case scenario is 85.31 USD. Compared to the current market price of 64.26 USD, Biomarin Pharmaceutical Inc is Undervalued by 25%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BMRN Relative Value
Base Case
85.31 USD
Undervaluation 25%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
98
vs Industry
57
Median 3Y
7.7
Median 5Y
7.8
Industry
7.7
Forward
4.3
vs History
65
vs Industry
2
Median 3Y
136.2
Median 5Y
99.8
Industry
22.7
Forward
30.7
vs History
98
vs Industry
3
Median 3Y
101.2
Median 5Y
103.3
Industry
21.6
vs History
vs Industry
2
Median 3Y
416.3
Median 5Y
79.2
Industry
25.2
vs History
98
vs Industry
30
Median 3Y
3.5
Median 5Y
3.5
Industry
2.5
vs History
98
vs Industry
49
Median 3Y
7.7
Median 5Y
7.8
Industry
7.7
Forward
4.1
vs History
98
vs Industry
43
Median 3Y
10
Median 5Y
10.4
Industry
9
vs History
84
vs Industry
2
Median 3Y
105
Median 5Y
114.5
Industry
4.2
Forward
20.7
vs History
41
vs Industry
1
Median 3Y
88.9
Median 5Y
-122
Industry
4.1
Forward
24.3
vs History
98
vs Industry
3
Median 3Y
100.8
Median 5Y
103.4
Industry
5.7
vs History
65
vs Industry
2
Median 3Y
319.2
Median 5Y
89.1
Industry
3.6
vs History
98
vs Industry
40
Median 3Y
3.2
Median 5Y
3.3
Industry
4.6

Multiples Across Competitors

BMRN Competitors Multiples
Biomarin Pharmaceutical Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
12.2B USD 4.4 38 23.4 29.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 083 264.3 -181 004.1 -219 796.6 -217 288.5
US
Abbvie Inc
NYSE:ABBV
312.7B USD 5.6 61.5 15.3 23.6
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 4.9 37.4 17.5 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 10.9 -241.6 24 25.2
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 4 891.9 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 849.9 -472 -514.1 -500.3
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 5.9 17.8 16.2 18
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.6 -58.7 -53
NL
argenx SE
XBRU:ARGX
34.5B EUR 18.5 -129.9 -104.5 -76.2
P/E Multiple
Earnings Growth
US
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Average P/E: 179.9
38
361%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 004.1 N/A
US
Abbvie Inc
NYSE:ABBV
61.5
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.6
42%
US
Gilead Sciences Inc
NASDAQ:GILD
891.9
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
US
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Average EV/EBITDA: 18.1
23.4
328%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 796.6 N/A
US
Abbvie Inc
NYSE:ABBV
15.3
29%
US
Amgen Inc
NASDAQ:AMGN
17.5
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
43%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.1 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
US
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Average EV/EBIT: 23.5
29.1
569%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 288.5 N/A
US
Abbvie Inc
NYSE:ABBV
23.6
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.3 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.2 N/A

See Also

Discover More
Back to Top